Business Context and Reporting Period
This Form 6-K filing by China SXT Pharmaceuticals, Inc. covers the month of October 2022. The report details the closing of a private placement transaction previously disclosed in September 2022.
Key Financial Metrics
The filing discloses specific transaction proceeds but does not provide comprehensive financial statements for the period.
- Gross Proceeds: $2,194,827.30
- Shares Issued: 1,625,798 ordinary shares
- Purchase Price: $1.35 per share
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide clear values for these metrics.
Material Changes
The primary material event is the successful closing of the Securities Purchase Agreement (SPA) with investor Zhijun Xiao. On October 11, 2022, the Company received the funds and issued the shares, satisfying all closing conditions. This transaction was executed in reliance on the exemption from registration requirements under Regulation S.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard regulatory disclosures regarding the transaction structure. No unusual items or contingencies were reported in this document.
Investor Verification Checklist
- Verify the final settlement of the $2,194,827.30 proceeds in the Company's cash accounts.
- Confirm the issuance and registration of the 1,625,798 ordinary shares with the relevant transfer agent.
- Review the impact of this equity issuance on total share count and potential dilution to existing shareholders.
- Check for any subsequent filings regarding the use of proceeds from this private placement.